| Name | Title | Contact Details |
|---|
The most uncluttered, user-friendly property portal. Find hundreds of 1000s of properties for sale & to rent from leading UK estate agents | OnTheMarket
Smith Jewelers is a Franklin, VA-based company in the Business Services sector.
Canadian Football League Players' Association is a Oakville, ON-based company in the Business Services sector.
Relax Gaming Group was founded in 2010 with the goal of simplifying B2B content delivery for the modern iGaming landscape. With standardised pricing and collaboration central to its ethos, its recent and rapid expansion has been conceived in order to deliver unparalleled global reach. Via a quick one-time integration, Relax Gaming now provides access to a roster of 1000+ casino games and a diverse range of proprietary products, including Poker, Bingo and its own rapidly expanding slot portfolio. The high-quality aggregated content is provided through its selected Silver Bullet (commercially represented) and Powered By (commercially independent) partners. Regulated markets are also at the heart of its growth strategy, with licences held in multiple jurisdictions including: the Malta Gaming Authority, the UK Gambling Commission and the Romanian National Gaming Office (ONJN). In addition to licensed operations, Relax Gaming fully supports regulated markets such as Denmark, Sweden, Estonia and Latvia.
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.